HOWL.NASDAQWerewolf Therapeutics, INC
DEF 14A: Werewolf Therapeutics Sets Date for 2024 Annual Stockholders Meeting
Sentiment:
Proxy Statement
Werewolf Therapeutics announces its 2024 annual meeting of stockholders to be held virtually on May 24, 2024, focusing on director elections and auditor ratification.
Summary
- Werewolf Therapeutics will hold its 2024 annual meeting of stockholders virtually on May 24, 2024, at 9:00 a.m. Eastern time.
- Stockholders of record as of April 1, 2024, are eligible to vote.
- The meeting will address the election of three Class III directors for terms expiring in 2027 and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- The board recommends voting FOR the election of the director nominees and FOR the ratification of the auditor appointment.
- Proxy materials are available online, and a Notice of Internet Availability was mailed around April 12, 2024.
- As of April 1, 2024, there were 43,347,363 shares of common stock issued and outstanding, each entitled to one vote.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, presenting necessary information for the annual meeting. The tone is professional and informative, with no significant positive or negative indicators.
Positives
- The company is providing a virtual meeting option to facilitate greater stockholder attendance and participation.
- The board of directors is recommending experienced individuals for election as Class III directors.
- The audit committee is recommending the ratification of an experienced independent registered public accounting firm.
Future Outlook
The board of directors will continue to evaluate the company's leadership structure and compensation policies to ensure they align with the company's strategic goals and stockholder interests.
Management Comments
- Daniel J. Hicklin, President and Chief Executive Officer, cordially invites stockholders to virtually attend the 2024 annual meeting.
Industry Context
This proxy statement is a standard part of corporate governance, ensuring transparency and providing stockholders with the information needed to make informed decisions about the company's direction.
Comparison to Industry Standards
- The director compensation program is designed to attract and retain highly qualified non-employee directors, which is a common practice among publicly traded companies.
- The company's clawback policy is compliant with Nasdaq listing standards, reflecting a commitment to accountability and ethical conduct.
- The company's approach to risk oversight, involving both the board and its committees, aligns with industry best practices for corporate governance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation Policy | Effective January 1, 2024, the board of directors adopted a non-employee director compensation policy that increased the annual cash retainers for the members of the board of directors to $40,000, increased the number of shares subject to the new director option grant to 35,000, and increased the number of shares subject to the annual option grant to 17,500. | January 1, 2024 | Aims to attract and retain highly qualified non-employee directors. |
Related Party Transactions
- In May 2022, Werewolf entered into a sublease agreement with Crossbow, to sublease to Crossbow the entirety of our office and laboratory space in Cambridge, Massachusetts.
- Dr. Morrison serves as the Chief Executive Officer of Crossbow and holds 5% of Crossbows outstanding common stock.
- Additionally, certain entities affiliated with MPM Capital are beneficial owners of Crossbow.
- Dr. Evnin co-founded MPM Capital and currently serves as Managing Director, and Dr. Morrison currently serves as Executive Partner.
Stakeholder Impact
- Stockholders are provided with information to make informed decisions regarding director elections and auditor ratification.
- The company's commitment to corporate governance and ethical conduct aims to protect the interests of all stakeholders.
Next Steps
- Stockholders are encouraged to vote their shares prior to the Annual Meeting.
- The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K.
Key Dates
| Date | Description |
|---|---|
| August 2018 | Michael B. Atkins, M.D. joined the Scientific Advisory Board |
| December 2017 | Werewolf Therapeutics entered into a royalty transfer agreement with MPM Oncology Impact Fund Charitable Foundation, Inc., or MPM Charitable Foundation, and UBS Optimus Foundation, or the Royalty Transfer Agreement. |
| October 2017 | Luke Evnin joined the board of directors |
| October 2017 | Daniel J. Hicklin joined the board of directors |
| August 2019 | Luke Evnin became chairman of the board of directors |
| August 2019 | Daniel J. Hicklin became President and Chief Executive Officer |
| November 2020 | Randi Isaacs became Chief Medical Officer |
| February 2021 | Timothy W. Trost became Chief Financial Officer and Treasurer |
| May 2021 | Michael Sherman joined the board of directors |
| June 2021 | Chulani Karunatilake became Chief Technology Officer |
| October 2021 | Meeta Chatterjee joined the board of directors |
| December 2020 | Derek DiRocco joined the board of directors |
| August 31, 2022 | Ernst & Young LLP appointed as independent registered public accounting firm, Deloitte & Touche LLP dismissed. |
| January 2024 | Michael Atkins elected to the nominating and corporate governance committee |
| April 1, 2024 | Record date for stockholder eligibility to vote at the Annual Meeting. |
| April 12, 2024 | Date of the notice of annual meeting. |
| May 24, 2024 | Date of the 2024 Annual Meeting of Stockholders. |
| December 13, 2024 | Deadline for stockholder proposals for inclusion in the 2025 proxy statement. |
| January 24, 2025 | Earliest date for receipt of stockholder proposals to be brought before the 2025 annual meeting. |
| February 23, 2025 | Latest date for receipt of stockholder proposals to be brought before the 2025 annual meeting. |
| March 25, 2025 | Deadline for shareholders to provide notice of intent to solicit proxies in support of director nominees other than the Company's nominees. |
Keywords
annual meeting, proxy statement, directors, stockholders, Ernst & Young, voting, governance, Werewolf Therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.